Aspen Aerogels (NYSE:ASPN) Stock Rating Lowered by Zacks Research

Aspen Aerogels (NYSE:ASPN) was downgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Several other analysts have also weighed in on ASPN. Barclays lowered their target price on shares of Aspen Aerogels from $6.00 to $4.00 and set an “underweight” rating for the company in a research note on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Aspen Aerogels in a report on Wednesday, October 8th. Finally, Canaccord Genuity Group cut their price target on Aspen Aerogels from $10.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, Aspen Aerogels currently has an average rating of “Hold” and an average price target of $12.67.

Aspen Aerogels Stock Performance

Aspen Aerogels stock opened at $3.67 on Monday. The stock’s 50 day moving average price is $7.17 and its 200 day moving average price is $6.75. Aspen Aerogels has a one year low of $3.47 and a one year high of $17.00. The company has a debt-to-equity ratio of 0.34, a quick ratio of 3.31 and a current ratio of 3.98. The firm has a market capitalization of $303.31 million, a PE ratio of -0.96 and a beta of 2.85.

Aspen Aerogels (NYSE:ASPN) last announced its earnings results on Thursday, November 6th. The construction company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.05). Aspen Aerogels had a negative net margin of 78.53% and a positive return on equity of 2.92%. The firm had revenue of $73.02 million during the quarter, compared to analysts’ expectations of $73.42 million. During the same quarter last year, the company posted ($0.17) earnings per share. Aspen Aerogels’s revenue for the quarter was down 37.8% compared to the same quarter last year. Aspen Aerogels has set its FY 2025 guidance at -4.150–4.050 EPS. As a group, sell-side analysts expect that Aspen Aerogels will post 0.17 EPS for the current fiscal year.

Hedge Funds Weigh In On Aspen Aerogels

Institutional investors have recently bought and sold shares of the stock. New York State Common Retirement Fund increased its position in shares of Aspen Aerogels by 2,073.6% in the first quarter. New York State Common Retirement Fund now owns 437,572 shares of the construction company’s stock worth $2,796,000 after acquiring an additional 417,441 shares in the last quarter. Nuveen LLC acquired a new stake in Aspen Aerogels during the 1st quarter valued at $1,083,000. Teacher Retirement System of Texas purchased a new stake in shares of Aspen Aerogels in the first quarter valued at $65,000. IFP Advisors Inc lifted its holdings in shares of Aspen Aerogels by 28.9% in the first quarter. IFP Advisors Inc now owns 26,716 shares of the construction company’s stock valued at $171,000 after purchasing an additional 5,997 shares in the last quarter. Finally, Palogic Value Management L.P. boosted its position in shares of Aspen Aerogels by 43.5% in the second quarter. Palogic Value Management L.P. now owns 610,000 shares of the construction company’s stock worth $3,611,000 after buying an additional 185,000 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Aspen Aerogels

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.